Close

Novartis (NVS) Announces Presentation of Significant Phase III MONALEESA-2 Data at ESMO 2016

Go back to Novartis (NVS) Announces Presentation of Significant Phase III MONALEESA-2 Data at ESMO 2016

Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of

October 8, 2016 8:00 AM EDT

EAST HANOVER, N.J., Oct. 8, 2016 /PRNewswire/ -- Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (median PFS, 95% CI (19.3 months - not reached) vs 14.7 months (13.0 - 16.5 months); HR=0.556;  p=0.00000329)1. Novartis announced today that the data will be featured in the official press briefing at the European Society for Medical Oncology (ESMO) 2016 Congress and presented as a... More